The Glivec International Patient Assistance Program (GIPAPä) that is supported by Novartis Oncology provides Glivec (imatinib), an innovative oral therapy for chronic myelogenous leukemia and gastrointestinal stromal tumours, at no cost to patients in developing countries who could otherwise not afford treatment. Using a novel direct-to-patient approach this program is currently successfully providing Glivec to underserved patients in 81 countries. A number of challenges were faced in the implementation of this program in countries where cancer is not a priority, and where the healthcare and other infrastructure can be very limited. By working within the existing healthcare system of each country, and with any national cancer control programme that may be in place, through careful selection of qualified institutions and physicians, while maintaining a global approach to ensure consistency and quality, GIPAP has become an efficient and sustainable access program. Novartis has made a long-term commitment to GIPAP, and is currently exploring new patient access programs for other drugs.
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glivec (imatinib)
The development of Glivec provided a breakthrough for two rare but life-threatening diseases. Glivec is a tyrosine kinase (TK) inhibitor that targets the abl, c-kit, and PDGF-R TKs, thereby specifically inhibiting the molecular abnormalities of Philadelphia chromosome-positive (Ph+) CML (Bcr-Abl TK), and of most GISTs (c-Kit). In a pivotal phase III trial which compared Glivec with interferon-a plus cytarabine in patients with newly-diagnosed chronic phase CML, Glivec induced major cytogenetic responses (McyR) in 87%, and complete cytogenetic responses (CCR) in 76% of patients [1] . These hematologic and cytogenetic responses were significantly better than interferon alfa plus cytarabine treatment, and Glivec was also associated with markedly better tolerability [1] . Studies have shown that Glivec is also associated with significant quality of life advantages over interferon treatment in CML [2] . The improved response rates with Glivec in CML have been shown to be durable and translate into prolonged survival. A recent 54-month update of the pivotal phase III trial indicated improved response rates with time with 98% of patients achieving a CHR, 92% an MCyR and 86% a CCR with 90% of patients alive and free from progression [3] . In a phase II randomised clinical trial of patients with advanced unresectable or metastatic GIST Glivec treatment led to a greater than 50% reduction in tumour size in more than half of the patients treated [4] . With a median follow-up of 4.4 years of follow-up, 68% of patients receiving Glivec achieved a complete or partial response (67% partial response, 1% complete response) and an additional 16% had stable disease. Median duration of response was 118 weeks and median overall survival of 58 months (4.8 years) [5] . Prior to the availability of Glivec, the only effective treatment option for GIST was surgery. Glivec has therefore markedly improved the treatment options for patients with GIST, and has led to better diagnosis and classification of this tumour and fundamentally changed the natural history of the disease. Glivec is currently symposium article indicated for treatment of newly diagnosed Ph+ CML and in patients with CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-a therapy. It is also indicated for adult patients with unresectable and/or metastatic malignant Kit (CD117)-positive GIST in the US, EU and a number of other countries and Kit (CD117)-positive GIST.
Glivec International Patient Assistance Program (GIPAP)
no-cost treatment for life-threatening cancers GIPAP provides imatinib at no cost to patients with Ph+ CML or GIST who have no access to reimbursement, are not insured and cannot afford to pay. This program is unique in that it has been specifically designed for this underserved patient population. It is a worldwide program for any eligible country which does not have a comprehensive reimbursement program. Glivec must be approved for the indication it will be used for in that country, and the program is not available in countries which have a licensed generic form of imatinib. GIPAP is currently operating in 81 countries in Asia, Latin America, Africa and Eastern Europe (Table 1) , and as of August 2005, it has provided treatment at no cost to 14 500 patients.
direct-to-patient model
GIPAP uses a unique direct-to-patient approach that operates within the existing healthcare system of each country, as opposed to typical donation programs that provide drugs through hospitals or some other third party distribution mechanism. Patients must be properly diagnosed by a GIPAP qualified physician. Every treatment center within which patients benefit from GIPAP is first evaluated and selected based primarily on their oncology and haematology expertise, and diagnostic and monitoring capacities. Physicians submit an application online on behalf of each patient. The physician is required to be involved in all stages of treatment, including diagnosis, prescription, and follow-up, which are all part of the comprehensive program that GIPAP supports in each country. Patient applications are assessed by the Max Foundation, a US-based non-profit patient organization specialised in CML, based on specific medical and financial requirements that follow World Health Organisation (WHO) guidelines on charitable donation programs. The Max Foundation also provides emotional care and education for patients. Novartis assumes responsibility for the donation and distribution of the drug to approved patients in qualified treatment centres. In countries where Novartis has no domestic operations, Axios International facilitates GIPAP through selection of institutions, management of product distribution, and applications for tax exemption. The administration of the program by independent third parties ensures independence in the evaluation and approval of GIPAP eligible patients. There are currently 782 physicians registered with GIPAP in 286 institutions across the world.
challenges to the implementation of GIPAP
A major obstacle to the implementation of GIPAP was the low priority that many governments of developing countries give to cancer. Other pressing health issues, often related to infectious diseases, displace cancer to a lower concern in many countries. However, cancer is a rapidly increasing issue throughout the developing world, where more than half of all cases of cancer in the world occur, and where survival rates are markedly lower than in developed countries [6] . It is hoped that the WHO Global Cancer Control Initiative [7] , which was established in response to the looming cancer epidemic in the developing world to assist countries to formulate and implement National Cancer Control Programs, will shift perceptions so that cancer is given increased priority by governments.
A second challenge was the limited healthcare infrastructure in many GIPAP countries. This included a lack of diagnostic capabilities which are essential for selecting patients for this targeted therapy. Therefore, institutions had to be carefully selected to ensure they could properly diagnose and monitor patients, and were accessible to most patients. Some countries only had very few qualified physicians -there is only one haematologist in Cambodia. Other infrastructure limitations often made it difficult to establish effective distribution channels, and limited communications with some physicians in locations where even phone lines were not always working. Logistical challenges like these were compounded by the complexity of the direct-to-patient approach, which requires the separate delivery of the correct dosage to each patient. GIPAP was not started in any country before full tax exemption was obtained for the imported Glivec, to ensure institutions or patients were not burdened with import taxes. Cultural and education differences meant that compliance was sometimes a barrier to effective treatment. Glivec can rapidly improve a patient's condition, and may sometimes lead to early discontinuation of the course of treatment. So GIPAP educates both patients and physicians in the importance of full compliance with treatment, and ensures individual patient tracking and regular follow-up of patients.
lessons learnt from GIPAP
To provide assistance to patients across the world, it is important to have an overriding global vision, to ensure consistency of the program at all sites. At the same time, there must be a flexible and local approach, working closely with local partners and adapting the program to the requirements of each individual country. The goal of a program like GIPAP must be to deliver sustainable access for patients. To achieve this, GIPAP operates within the healthcare environment of each country, and where in place, any national cancer control programme, supplementing the existing system rather than substituting it. Patient education, and close monitoring and follow-up of patients, all of which are an integral part of GIPAP, are also essential to ensure proper compliance. The direct-to-patient model has been manageable for the treatment of two rare diseases with an oral drug, but for other diseases specific access models would need to be developed.
GIPAP in Thailand
Although Thailand is considered a developing country, with a per capita income of only approximately US$8100, the healthcare infrastructure is good. The overall health system performance was ranked 47th among all other member states of the World Health Organization, the second highest ranking after Singapore among South East Asian countries [8] . The life expectancy at birth is 70.4 for women and 66.0 for men, also one of the highest rates in the region [8] . The estimated ratio of physicians to population is one per 3300 persons [9] , and there is a good supply of government and private hospitals and clinics. However, health care coverage remains uneven. Government officials and social security beneficiaries have access to full health insurance, but the majority of the population is covered under the national health care insurance universal coverage, which only offers basic treatment. Therefore, only about 10% of the population would have access to cancer treatment with innovative drugs like Glivec.
There are approximately 120 new cases of CML per year that present to the nine university hospitals that offer treatment for this cancer, and around 500 total in all of Thailand. While treatment options include bone marrow transplant, hydroxyurea, interferon and Glivec, financial constraints mean that the majority of patients only receive hydroxyurea for symptomatic treatment.
There were a number of obstacles to getting GIPAP started in Thailand. A core group of leading haematologists in the country met to address key tasks including obtaining tax exemption, the selection of institutions and patients, patient follow-up and education and other logistical issues. It took almost 1 year to identify the correct process to obtain tax exemption. Currently, all import procedures still take more than three months, because authorizations must be separately obtained from the hospital director, the Thai Federal Drug Administration, and Thai Customs.
GIPAP commenced in Thailand in 2003, and is currently operating in 90 centres with more than 60 enrolled physicians. To date, more than 500 patients have already been treated with Glivec who otherwise would not have had access to this innovative and effective treatment. At Ramathibodi Hospital, about 100 patients are currently being treated with Glivec through GIPAP. One case illustrates the impact GIPAP can have on patients' lives. A 46-year-old woman who was diagnosed with CML was unable to keep her job because of chronic tiredness related to her disease. As a result of this, her husband remarried, leaving her without any financial support. Following the established procedures, her physician (SJ) applied directly to GIPAP on her behalf successfully. A 6-month course of treatment with Glivec left her disease in remission, she was able to return to work, and is again financially independent. Beyond application, the physician is also responsible for ensuring regular follow-up of patients, for maintaining all records related to drug supply, for reporting any serious adverse events. In Thailand, GIPAP is using a workable donation model to provide Glivec to CML patients who would otherwise have no effective treatment options for this life-threatening disease, allowing them to remain active members of society.
conclusions
GIPAP is an innovative access model that has proven to be effective and sustainable. There were a number of challenges to providing Glivec directly to patients in low-resource and culturally very diverse countries, and it is expected that each patient access program will face unique obstacles. However, key to the success of GIPAP is the long-term commitment made by the partners, operating within the healthcare system of each country to leverage existing resources, and close monitoring of each patient as part of a comprehensive program of ongoing monitoring, awareness and education. Patient access models for other drugs are currently being explored. 
